Bélec L, Maletinska L, Slaninová J, Lubell W D
Département de chimie, Université de Montréal, Montréal, Québec, Canada.
J Pept Res. 2001 Sep;58(3):263-73. doi: 10.1034/j.1399-3011.2001.00932.x.
Six [Pen(6)]oxytocin analogs were synthesized by substituting penicillamine for cysteine in oxytocin, [Mpa(1)]oxytocin, [dPen(1)]oxytocin, [5-t-BuPro(7)]oxytocin, [Mpa(1), 5-t-BuPro(7)]oxytocin and [dPen(1), 5-t-BuPro(7)]oxytocin. When tested in the uterotonic test in vitro [Pen(6)]oxytocin, [Pen(6), 5-t-BuPro(7)]oxytocin, [Mpa(1), Pen(6)]oxytocin and [Mpa(1), Pen(6), 5-t-BuPro(7)]oxytocin, all were found to possess both agonistic and antagonistic properties. Their agonistic potency ranged from negligible (0.08 IU/mg) to low (5.85 IU/mg) and their antagonistic potency (pA2) was estimated to range from 6.6 to 7.9. [dPen(1), Pen(6)]Oxytocin and [dPen(1), Pen(6), 5-t-BuPro(7)]oxytocin were found to be pure antagonists with similarly high pA2 values of approximately 8.2. Replacement of proline by 5-tert-butylproline increased binding affinity by a factor of two in [Pen(6)]oxytocin and had no influence on the binding affinity of [Mpa(1), Pen(6)]oxytocin and [dPen(1), Pen(6)]oxytocin. Assignment of the proton signals for prolyl amide cis- and trans-isomers by NMR experiments in water indicated that the Pen(6)-5-tert-BuPro(7) peptide bond cis-isomer population was augmented relative to the prolyl peptides and measured, respectively, at 20, 35 and 35% in the 5-tert-butylproline(7) analogs of [Pen(6)]oxytocin, [Mpa(1), Pen(6)]oxytocin and [dPen(1), Pen(6)]oxytocin. This augmentation in cis-isomer population was correlated with a 21-fold reduction in the agonistic potency and 2-fold augmentation in antagonistic potency for [Pen(6), 5-t-BuPro(7)]oxytocin relative to [Pen(6)]oxytocin. Augmentation of cis-isomer population was also correlated to reduced agonist potency without effect on antagonism on conversion of [Mpa(1), Pen(6)]oxytocin to [Mpa(1), Pen(6), 5-t-BuPro(7)]oxytocin. In the potent oxytocin antagonist, [dPen(1), Pen(6)]oxytocin, substitution of 5-tert-butylproline for proline augmented the cis-isomer population without affecting antagonistic potency. The synthesis and evaluation of [Pen(6)]oxytocin and [Pen(6), 5-t-BuPro(7)]oxytocin analogs 1-6 indicated that steric interactions influenced agonist and antagonist activity by modifying peptide conformation. Augmentations in the prolyl cis-isomer population caused by 5-tert-butylproline occurred concurrently with enhanced or maintained antagonistic potency and binding affinity and reduced agonistic potency.
通过用青霉胺替代催产素、[Mpa(1)]催产素、[dPen(1)]催产素、[5-t-BuPro(7)]催产素、[Mpa(1), 5-t-BuPro(7)]催产素和[dPen(1), 5-t-BuPro(7)]催产素中的半胱氨酸,合成了六种[Pen(6)]催产素类似物。在体外子宫收缩试验中进行测试时,发现[Pen(6)]催产素、[Pen(6), 5-t-BuPro(7)]催产素、[Mpa(1), Pen(6)]催产素和[Mpa(1), Pen(6), 5-t-BuPro(7)]催产素均具有激动和拮抗特性。它们的激动效力范围从可忽略不计(0.08 IU/mg)到较低(5.85 IU/mg),其拮抗效力(pA2)估计在6.6至7.9之间。发现[dPen(1), Pen(6)]催产素和[dPen(1), Pen(6), 5-t-BuPro(7)]催产素是纯拮抗剂,具有相似的高pA2值,约为8.2。在[Pen(6)]催产素中,用5-叔丁基脯氨酸替代脯氨酸使结合亲和力提高了两倍,而对[Mpa(1), Pen(6)]催产素和[dPen(1), Pen(6)]催产素的结合亲和力没有影响。通过在水中进行核磁共振实验对脯氨酰胺顺式和反式异构体的质子信号进行归属表明,相对于脯氨酰肽,Pen(6)-5-叔丁基脯氨酸(7)肽键顺式异构体的比例增加,在[Pen(6)]催产素、[Mpa(1), Pen(6)]催产素和[dPen(1), Pen(6)]催产素的5-叔丁基脯氨酸(7)类似物中分别测得为20%、35%和35%。相对于[Pen(6)]催产素,[Pen(6), 5-t-BuPro(7)]催产素中顺式异构体比例的增加与激动效力降低21倍和拮抗效力增加2倍相关。顺式异构体比例的增加也与激动剂效力降低相关,而在[Mpa(1), Pen(6)]催产素转化为[Mpa(1), Pen(6), 5-t-BuPro(7)]催产素时对拮抗作用没有影响。在强效催产素拮抗剂[dPen(1), Pen(6)]催产素中,用5-叔丁基脯氨酸替代脯氨酸增加了顺式异构体的比例,但不影响拮抗效力。[Pen(6)]催产素和[Pen(6), 5-t-BuPro(7)]催产素类似物1 - 6的合成与评估表明,空间相互作用通过改变肽构象影响激动剂和拮抗剂活性。由5-叔丁基脯氨酸引起的脯氨酰顺式异构体比例的增加与拮抗效力和结合亲和力的增强或维持以及激动效力的降低同时发生。